ALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025

5/2/25 8:00:00 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $ALXO alert in real time by email

SOUTH SAN FRANCISCO, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (NASDAQ:ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced plans to report its first quarter 2025 financial results on Thursday, May 8th, 2025, before market open.

The company will not be hosting a teleconference in conjunction with its financial results press release.

About ALX Oncology

ALX Oncology (NASDAQ:ALXO) is a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives. ALX Oncology's lead therapeutic candidate, evorpacept, has demonstrated potential to serve as a cornerstone therapy upon which the future of immuno-oncology can be built. Evorpacept is currently being evaluated across multiple ongoing clinical trials in a wide range of cancer indications. ALX Oncology's second pipeline candidate, ALX2004, is a novel EGFR-targeted antibody-drug conjugate with a differentiated mechanism of action and is anticipated to enter Phase 1 trials mid-2025. More information is available at www.alxoncology.com and on LinkedIn @ALX Oncology.

Investor Relations Contact:

Elhan Webb, CFA, IR Consultant

[email protected]

Media Contact:

Audra Friis, Sam Brown, Inc.

[email protected]

(917) 519-9577

Get the next $ALXO alert in real time by email

Recent Analyst Ratings for

$ALXO

Date	Price Target	Rating	Analyst
3/6/2025	$2.00 → $3.00	Hold → Buy	Jefferies
12/19/2024	$12.00 → $2.00	Buy → Hold	Jefferies
3/8/2024	$10.00 → $14.00	Buy → Hold	Stifel
12/8/2023	$8.00 → $18.00	Hold → Buy	Jefferies
3/1/2022	$60.00 → $36.00	Buy	Stifel
12/22/2021	$65.00 → $25.00	Buy → Hold	Jefferies
9/30/2021	$106.00	Buy	Stifel

More analyst ratings

ALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025

Chat with this insight

Recent Analyst Ratings for
$ALXO

$ALXO
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Director Hemrajani Rekha bought $46,404 worth of shares (30,000 units at $1.55), increasing direct ownership by 1,000% to 33,000 units (SEC Form 4)

Amendment: CHIEF FINANCIAL OFFICER Garcia Peter S bought $102,338 worth of shares (12,000 units at $8.53), increasing direct ownership by 11% to 122,348 units (SEC Form 4)

CHIEF FINANCIAL OFFICER Garcia Peter S bought $102,338 worth of shares (12,000 units at $8.53), increasing direct ownership by 11% to 122,348 units (SEC Form 4)

$ALXO
SEC Filings

ALX Oncology Holdings Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

Amendment: SEC Form SCHEDULE 13G/A filed by ALX Oncology Holdings Inc.

Amendment: SEC Form SCHEDULE 13G/A filed by ALX Oncology Holdings Inc.

$ALXO
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by SVP, FINANCE AND CAO Pinto Shelly

SEC Form 4 filed by Chief Medical Officer Sandler Alan B.

SEC Form 4 filed by Chief Financial Officer Shantharam Harish

ALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025

Chat with this insight

Recent Analyst Ratings for $ALXO

$ALXO Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Director Hemrajani Rekha bought $46,404 worth of shares (30,000 units at $1.55), increasing direct ownership by 1,000% to 33,000 units (SEC Form 4)

Amendment: CHIEF FINANCIAL OFFICER Garcia Peter S bought $102,338 worth of shares (12,000 units at $8.53), increasing direct ownership by 11% to 122,348 units (SEC Form 4)

CHIEF FINANCIAL OFFICER Garcia Peter S bought $102,338 worth of shares (12,000 units at $8.53), increasing direct ownership by 11% to 122,348 units (SEC Form 4)

$ALXO SEC Filings

ALX Oncology Holdings Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

Amendment: SEC Form SCHEDULE 13G/A filed by ALX Oncology Holdings Inc.

Amendment: SEC Form SCHEDULE 13G/A filed by ALX Oncology Holdings Inc.

$ALXO Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by SVP, FINANCE AND CAO Pinto Shelly

SEC Form 4 filed by Chief Medical Officer Sandler Alan B.

SEC Form 4 filed by Chief Financial Officer Shantharam Harish

Recent Analyst Ratings for
$ALXO

$ALXO
Insider Purchases

$ALXO
SEC Filings

$ALXO
Insider Trading